Novocure Ebitda from 2010 to 2024

NVCR Stock  USD 31.54  0.56  1.74%   
Novocure EBITDA yearly trend continues to be relatively stable with very little volatility. EBITDA is likely to grow to about -167.1 M this year. During the period from 2010 to 2024, Novocure EBITDA destribution of quarterly values had r-value of (0.16) from its regression line and median of (68,486,000). View All Fundamentals
 
EBITDA  
First Reported
2014-03-31
Previous Quarter
-30.7 M
Current Value
-29.6 M
Quarterly Volatility
18.3 M
 
Yuan Drop
 
Covid
Check Novocure financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novocure's main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.8 M, Interest Expense of 3.2 M or Selling General Administrative of 87.6 M, as well as many indicators such as Price To Sales Ratio of 2.96, Dividend Yield of 0.0 or PTB Ratio of 4.16. Novocure financial statements analysis is a perfect complement when working with Novocure Valuation or Volatility modules.
  
Check out the analysis of Novocure Correlation against competitors.
To learn how to invest in Novocure Stock, please use our How to Invest in Novocure guide.

Latest Novocure's Ebitda Growth Pattern

Below is the plot of the Ebitda of Novocure over the last few years. It is Novocure's EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novocure's overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Pretty Stable
   Ebitda   
       Timeline  

Novocure Ebitda Regression Statistics

Arithmetic Mean(68,135,450)
Coefficient Of Variation(85.38)
Mean Deviation40,416,833
Median(68,486,000)
Standard Deviation58,175,914
Sample Variance3384.4T
Range221.2M
R-Value(0.16)
Mean Square Error3553.5T
R-Squared0.03
Significance0.57
Slope(2,059,147)
Total Sum of Squares47382.1T

Novocure Ebitda History

2024-167.1 M
2023-175.9 M
2022-78.9 M
2021-34.1 M
202045.3 M
20197.5 M
2018-24.7 M

About Novocure Financial Statements

Novocure shareholders use historical fundamental indicators, such as Ebitda, to determine how well the company is positioned to perform in the future. Although Novocure investors may analyze each financial statement separately, they are all interrelated. The changes in Novocure's assets and liabilities, for example, are also reflected in the revenues and expenses on on Novocure's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
EBITDA-175.9 M-167.1 M

Additional Tools for Novocure Stock Analysis

When running Novocure's price analysis, check to measure Novocure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novocure is operating at the current time. Most of Novocure's value examination focuses on studying past and present price action to predict the probability of Novocure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novocure's price. Additionally, you may evaluate how the addition of Novocure to your portfolios can decrease your overall portfolio volatility.